Ascelia Pharma AB Financial Update
Ascelia Pharma AB, a biotechnology company listed on the Swedish Stock Exchange, has recently reported a significant increase in its net loss for the second quarter of 2025. The company, which focuses on developing medications for liver metastases and gastric cancer, disclosed a net loss after tax of SEK -23.0 million for the quarter, compared to SEK -13.3 million in the same period the previous year. The loss per share was reported at SEK -0.20, an improvement from SEK -0.39 in the prior year.
Despite the increased net loss, there is a positive outlook for Ascelia Pharma due to advancements in its Orviglance application. The company is nearing the completion of the electronic configuration of the file, with a submission expected by the end of August or early September. This progress is seen as a minor delay from the initial target, and it is anticipated to elicit a positive reaction in the share price once the formal submission is made.
As of August 19, 2025, Ascelia Pharma’s share price closed at SEK 4.58, with a 52-week high of SEK 5.23 on August 4, 2025, and a low of SEK 2 on September 12, 2024. The company’s market capitalization stands at SEK 531,396,799.
Ascelia Pharma continues to focus on its strategic initiatives in the healthcare sector, aiming to bring innovative treatments to patients in Sweden and potentially beyond. The company’s progress with the Orviglance application is a key development that stakeholders are closely monitoring.